AbbVie Inc. vs General Motors Company: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and General Motors Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating General Motors Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and General Motors Company is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $185.0B for General Motors Company, while their respective market capitalizations stand at $451.5B and $73.7B. AbbVie Inc. is headquartered in United States and General Motors Company operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

General Motors Company: GM's fiscal 2025 results show a huge revenue base with thinner earnings. Revenue was $185.02 billion, down slightly from fiscal 2024, while net income attributable to stockholders fell to $2.70 billion amid EV investment, China pressure, restructuring, and autonomous-vehicle uncertainty.

AbbVie Inc. and General Motors Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and General Motors Company.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

General Motors Company business model: General Motors makes money by designing, manufacturing, wholesaling, financing, and servicing vehicles. The core profit engine is North American trucks and SUVs, supported by GM Financial, parts and service, OnStar subscriptions, software features, fleet sales, and international operations.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of General Motors Company.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

General Motors Company competitive advantage: GM's advantage is its North American truck and large-SUV franchise, manufacturing scale, supplier base, dealer network, financing arm, and decades of connected-vehicle data through OnStar. Those assets fund the transition even as EV economics remain difficult.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and General Motors Company each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

General Motors Company growth strategy: The strategy is to protect high-margin trucks and SUVs, scale Ultium-based EVs where demand is profitable, expand software and services, use GM Financial to support sales, and focus capital on markets where GM has a realistic path to returns.

A closer look at the financial trajectory of AbbVie Inc. and General Motors Company rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

General Motors Company: Fiscal 2025 revenue was $185.02 billion, down from $187.44 billion in fiscal 2024. Net income attributable to stockholders was $2.70 billion, and GM reported total worldwide employment of 155,000 people at year-end.